Olatec Therapeutics

About Olatec Therapeutics

Olatec is a privately held biopharmaceutical company dedicated to improving the health and well-being of patients worldwide by developing and commercializing a platform of safe and effective pharmaceuticals targeting a broad spectrum of inflammatory diseases.

Products & Services

Dapansutrile (OLT1177®):Olatec's lead compound, a safe and effective NLRP3 inhibitor, showing clinical benefits and reduction in systemic inflammation in human studies, targeting a broad spectrum of inflammatory diseases such as arthritis, heart failure, asthma, Alzheimer's, and more.

Pharmaceutical Pipeline:Includes approximately 40 pharmaceutical candidates in development, protected by a portfolio of over 180 global patents and patent applications.

Specialties

Inflammation and Immunology NLRP3 Inhibitor Therapeutics Treatment of Inflammatory Diseases

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 40000000 MR: - FA: 40 million FAN: 40000000	D: 2023-02-23 FD: 2023-02-23	3 investors

Series A Latest

2023-02-23

$40.0M

3 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

Damaris B. Skouras

Founder, Chairman, Chief Executive Officer

C

Craig T. Basson

Director

A

Andrea Cunningham

Director

J

John F. Otto, Jr.

Director

G

Gregory K. Palm

Director

L

Lucio C. Rovati

CEO and CSO of Rottapharm Biotech S.r.l., Visiting Professor of Clinical Pharmacology

View 32 more team members with Pro

Unlock Full Team Directory

Recent News